0 items

in your cart
$0.00

Prescription Drug Search

Strengths available for Tykerb:

Tykerb 250mg

Search for a drug:

 

Browse Alphabetically:

A · B · C · D · E · F · G · H · I · J · K · L · M · N
O · P · Q · R · S · T · U · V · W · X · Y · Z · #

Information about ExpressMedsCanada.com

SSL Secured Website Certified Global Pharmacy Network Hacker Proof: Safe Shopping Experience 5th Anniversary 2002-2007

List of countries where we can ship Tykerb:

  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Austria
  • Azerbaijan
  • Barbados
  • Belize
  • Bolivia
  • Cayman Islands
  • Chile
  • China
  • Colombia
  • Croatia
  • Denmark
  • Egypt
  • Germany
  • Greenland
  • Guadeloupe
  • Guatemala
  • Hong Kong
  • Iceland
  • India
  • Iran
  • Ireland
  • Jamaica
  • Jordan
  • Korea, South
  • Latvia
  • Lebanon
  • Liechtenstein
  • Poland
  • Saudi Arabia
  • Serbia
  • Seychelles
  • Thailand
  • Trinidad and Tobago
  • Turkey
  • United Arab Emirates
  • United Kingdom, UK
  • United States, US
View All Countries

Latest news releases on Tykerb:

Study Combines Lapatinib With Cetuximab to Overcome Resistance in EGFR-Driven Tumors, New Research Suggests - Science Daily

Lapatinib, marketed as Tykerb, is FDA-approved for the treatment of some types of breast cancer. Sixteen patients whose tumors are driven by EGFR were enrolled in the study and received the established dose of cetuximab (intravenously once a week).

Lapatinib blocks the growth of breast cancer cells that spread to the brain in a mouse model - Xagena Medical News

The small molecule used in the studies was the drug Lapatinib ( Tykerb ), which disrupts an important breast cancer metabolic process called the Her2/neu signaling pathway. Lapatinib inhibits the activation of growth signaling proteins and their signaling ...

GSK melanoma drugs may steal market from Roche - msnbc.com

Britain's biggest drugmaker has made oncology a priority for drug development but has struggled to achieve significant sales, with Tykerb for breast cancer, in particular, failing to meeting early lofty sales forecasts.

Hong Kong launches cancer drug relief fund - Channel NewsAsia

GSK's Hycamtin, used to treat cervical and ovarian cancer, as well as Tykerb, used for breast cancer treatment, will be covered under the initial programme. The two drugs would each cost an average of over US$2,500 per month for a full course of treatment.

ASCO Preview: Eight Cancer Drugs to Watch at the Big Show - Xconomy

These women had previously gotten Herceptin, and were randomly assigned to get either T-DM1 or a combo of GlaxoSmithKline’s lapatinib (Tykerb) and capecitabine (Xeloda) chemotherapy. Partly because this drug is working against a high-profile ...

Roche Drugs To Be Key Focus At Upcoming US Cancer Meeting ASCO - Smart Money

In March, Roche said women whose breast cancer had spread despite earlier treatment lived longer without their disease getting worse when treated with T-DM1, compared to those who received a combination of GlaxoSmithKline PLC's (GSK) Tykerb plus chemotherapy.

Taiwan Pharmaceuticals and Healthcare Report Q2 2012 - new market research report - Transworld News

Roches Herceptin (trastuzumab) is on the coverage list but the patients also want GlaxoSmithKlines Tykerb (lapatinib) to be covered. Without the NHI in Taiwan, the cost of using Herceptin would be approximately TWD78,000 (US$2,575) a month, with the drug ...

NeuVax Developer Dr. Peoples Eliminates Speculation For Facts - Seekingalpha.com

Companies and/or drugs discussed in this interview: Dendreon's Provenge, Bristol-Myers' (BMY) Yervoy, Eli Lilly's Raloxifene, GlaxoSmithKiline's Tykerb, and Galena BioPharma's NeuVax.

Drugs To Watch At ASCO 2012 - Seekingalpha.com

Patients and physicians alike will be very receptive to T-DM1 for 2nd line patients as the currently approved alternative (Xeloda+Tykerb) is considered minimally effective and too toxic. In fact, even if T-DM1 had a comparable PFS to Xeloda+Tykerb ...

Syndax Pharma adds new board member - Mass High Tech

In April, the company announced that it had started a Phase 1/2 study combining its entinostat with lapatinib ditosylate, a breast cancer drug by Glaxo Smith Kline sold as Tykerb. The study involved patients with locally-recurrent or distant ...

Customer Service
1-866-799-3435 - Use Discount Code 7500 | Contact Form
Copyright © 2012 ExpressMedsCanada.com All rights reserved. Disclaimer | Privacy Policy
Accepted Credit Cards and Payment: VISA, MASTERCARD and eCHECK